Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis
American Journal of Cardiovascular Drugs · 08.08.2026
DOI: 10.1007/s40256-026-00813-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 08.08.2026. Verfasst von Jing Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertension, Peking University People's Hospital, Beijing, 100044, China. jingliu@pku.edu.cn. Die Arbeit nennt 63 Literaturangaben. Gefördert von: Hasten Biopharmaceutical Company.
Abstract (Originalsprache)
INTRODUCTION: While not all angiotensin receptor blockers (ARBs) exhibit inverse agonistic activity, certain ARBs with this property may offer greater potential for blood pressure (BP) reduction compared with ARBs without inverse agonism. This study aimed to evaluate the antihypertensive efficacy and safety of ARBs with or without inverse agonism. METHODS: A systematic literature review and network meta-analysis identified randomized clinical trials (RCTs) of first-line monotherapy for mild-to-moderate hypertension: azilsartan medoxomil (AZL-M), candesartan, olmesartan, losartan, valsartan, telmisartan, irbesartan, allisartan isoproxil, sacubitril/valsartan, sacubitril/allisartan, or placebo. Treatments were grouped as ARBs with or without inverse agonism, angiotensin receptor neprilysin inhibitors (ARNIs), and placebo. AZL-M was separately analyzed as part of ARBs with inverse agonism. BP changes and adverse events (AEs) were assessed. RESULTS: Of 2659 RCTs screened, 23 studies were analyzed. ARBs with inverse agonism demonstrated superior systolic BP and diastolic BP reductions compared with ARBs without inverse agonism, ARNIs, and placebo. When analyzed separately, AZL-M significantly outperformed ARBs without inverse agonism in systolic BP and diastolic BP reduction and was superior to other ARBs with inverse agonism in systolic BP reduction. Surface under the cumulative ranking curves (SUCRA) indicated AZL-M had the highest probability of being the best treatment for systolic BP (98%) and diastolic BP (95%) reduction. CONCLUSIONS: This study supports that ARBs with inverse agonism, especially AZL-M, have a better BP-lowering efficacy compared with ARBs without inverse agonism and ARNIs, while maintaining favorable safety profiles. Future research is encouraged to explore the effects on long-term outcomes, combination therapies, and safety in diverse populations.
Autor:innen und Institutionen
- Department of Hypertension, Peking University People's Hospital, Beijing, 100044, China. jingliu@pku.edu.cn.
- Vascular Health Research Center, Peking University Health Science Center, Beijing, 100083, China. jingliu@pku.edu.cn.
- Department of Hypertension, Peking University People's Hospital, Beijing, 100044, China.
- EVERSANA (Shanghai) Consulting Services Co., Ltd., Shanghai, China.
Förderung
- Hasten Biopharmaceutical Company
Zitieren
APA
Liu, J., Geng, J., Liu, J., Hu, L., Du, H., Hung, I. T. A., & Fang, J. (2026). Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-026-00813-9
Vancouver
Liu J, Geng J, Liu J, Hu L, Du H, Hung ITA, et al. Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. American Journal of Cardiovascular Drugs. 2026. doi:10.1007/s40256-026-00813-9
BibTeX
@article{Liu2026,
author = {Liu, Jing and Geng, Jialu and Liu, Jiakun and Hu, Lei and Du, Huimin and Hung, Ivan Tjong A and Fang, Jia},
title = {Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis},
journal = {American Journal of Cardiovascular Drugs},
year = {2026},
doi = {10.1007/s40256-026-00813-9}
}
EUVIMED